For help on how to get the results you want, see our search tips.
377 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Periodic safety update report single assessments Remove Periodic safety update report single assessments filter
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Lojuxta (updated)
Lomitapide, Hypercholesterolemia
Date of authorisation: 31/07/2013,
, 
, Revision: 18, Authorised, Last updated: 06/11/2023
-
List item
Human medicine European public assessment report (EPAR): Skytrofa (previously Lonapegsomatropin Ascendis Pharma) (updated)
Lonapegsomatropin, Growth and Development
Date of authorisation: 11/01/2022,, 
, Revision: 4, Authorised, Last updated: 06/11/2023
-
List item
Human medicine European public assessment report (EPAR): Tavneos (updated)
Avacopan, Microscopic Polyangiitis; Wegener Granulomatosis
Date of authorisation: 11/01/2022,, , Revision: 4, Authorised, Last updated: 03/11/2023
-
List item
Human medicine European public assessment report (EPAR): Calquence (updated)
Acalabrutinib, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 05/11/2020,, Revision: 7, Authorised, Last updated: 03/11/2023
-
List item
Human medicine European public assessment report (EPAR): Venclyxto (updated)
Venetoclax, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 04/12/2016,, Revision: 16, Authorised, Last updated: 31/10/2023
-
List item
Human medicine European public assessment report (EPAR): Comirnaty (updated)
Single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2, COVID-19 virus infection
Date of authorisation: 21/12/2020,
, , Revision: 45, Authorised, Last updated: 31/10/2023
-
List item
Human medicine European public assessment report (EPAR): Minjuvi (updated)
Tafasitamab, Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 26/08/2021,, , 
, Revision: 4, Authorised, Last updated: 31/10/2023
-
List item
Human medicine European public assessment report (EPAR): Benlysta (updated)
belimumab, Lupus Erythematosus, Systemic
Date of authorisation: 13/07/2011,, Revision: 31, Authorised, Last updated: 31/10/2023
-
List item
Human medicine European public assessment report (EPAR): COVID-19 Vaccine (inactivated, adjuvanted) Valneva
SARS-CoV-2 virus (inactivated) Wuhan strain hCoV-19 / Italy / INMI1-isl / 2020, COVID-19 virus infection
Date of authorisation: 24/06/2022,, Revision: 6, Authorised, Last updated: 30/10/2023
-
List item
Human medicine European public assessment report (EPAR): Yescarta
Axicabtagene ciloleucel, Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse
Date of authorisation: 23/08/2018,, , Revision: 12, Authorised, Last updated: 30/10/2023
-
List item
Human medicine European public assessment report (EPAR): Xofigo
radium (223Ra) dichloride, Prostatic Neoplasms
Date of authorisation: 13/11/2013,, Revision: 14, Authorised, Last updated: 30/10/2023
-
List item
Human medicine European public assessment report (EPAR): Tecvayli
Teclistamab, Multiple Myeloma
Date of authorisation: 23/08/2022,, , Revision: 2, Authorised, Last updated: 30/10/2023
-
List item
Human medicine European public assessment report (EPAR): Raxone
idebenone, Optic Atrophy, Hereditary, Leber
Date of authorisation: 08/09/2015,, , , Revision: 9, Authorised, Last updated: 30/10/2023
-
List item
Human medicine European public assessment report (EPAR): Adtralza
Tralokinumab, Dermatitis, Atopic
Date of authorisation: 17/06/2021,, Revision: 4, Authorised, Last updated: 30/10/2023
-
List item
Human medicine European public assessment report (EPAR): Lemtrada
alemtuzumab, Multiple Sclerosis
Date of authorisation: 12/09/2013,, Revision: 22, Authorised, Last updated: 30/10/2023
-
List item
Human medicine European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)
Dinutuximab beta, Neuroblastoma
Date of authorisation: 08/05/2017,, , , Revision: 16, Authorised, Last updated: 27/10/2023
-
List item
Human medicine European public assessment report (EPAR): Byfavo
remimazolam besilate, Conscious Sedation
Date of authorisation: 26/03/2021,, Revision: 6, Authorised, Last updated: 26/10/2023
-
List item
Human medicine European public assessment report (EPAR): Piqray
Alpelisib, Breast Neoplasms
Date of authorisation: 27/07/2020,, Revision: 10, Authorised, Last updated: 26/10/2023
-
List item
Human medicine European public assessment report (EPAR): Defitelio
defibrotide, Hepatic Veno-Occlusive Disease
Date of authorisation: 18/10/2013,, , Revision: 15, Authorised, Last updated: 25/10/2023
-
List item
Human medicine European public assessment report (EPAR): Blenrep
belantamab mafodotin, Multiple Myeloma
Date of authorisation: 25/08/2020,, , , Revision: 7, Authorised, Last updated: 25/10/2023
-
List item
Human medicine European public assessment report (EPAR): Heplisav B
hepatitis B surface antigen, Hepatitis B
Date of authorisation: 18/02/2021,, Revision: 5, Authorised, Last updated: 24/10/2023
-
List item
Human medicine European public assessment report (EPAR): Revlimid
lenalidomide, Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes
Date of authorisation: 14/06/2007,, Revision: 51, Authorised, Last updated: 20/10/2023
-
List item
Human medicine European public assessment report (EPAR): Fintepla
Fenfluramine hydrochloride, Epilepsies, Myoclonic
Date of authorisation: 18/12/2020,, , Revision: 7, Authorised, Last updated: 20/10/2023
-
List item
Human medicine European public assessment report (EPAR): Sunosi
solriamfetol hydrochloride, Narcolepsy; Sleep Apnea, Obstructive
Date of authorisation: 16/01/2020,, Revision: 8, Authorised, Last updated: 19/10/2023
-
List item
Human medicine European public assessment report (EPAR): Lytgobi
Futibatinib, Cholangiocarcinoma
Date of authorisation: 04/07/2023,, , Revision: 1, Authorised, Last updated: 19/10/2023